Thursday, 07 April 2011 11:06
The Spanish Working Group on Fast Track Surgery (GERM) has always considered Goal-directed fluidtherapy to be a fundamental step of any enhanced recovery programme, one of the last NICE's recommendations (that covers over 800,000 surgical patients), strongly supports our view.
NICE's guidance states:
"1.1 The case for adopting the CardioQ-ODM in the NHS, when used as described in 1.2, is supported by the evidence. There is a reduction in post-operative complications, use of central venous catheters and in-hospital stay (with no increase in the rate of re-admission or repeat surgery) compared with conventional clinical assessment with or without invasive cardiovascular monitoring. The cost saving per patient, when the CardioQ-ODM is used instead of a central venous catheter in the peri-operative period, is about £1100 based on a 7.5-day hospital stay.
1.2 The CardioQ-ODM should be considered for use in patients undergoing major or high-risk surgery or other surgical patients in whom a clinician would consider using invasive cardiovascular monitoring."